Corient Private Wealth
IMNM icon

Corient Private Wealth’s Immunome IMNM Stock Holding History

Corient Private Wealth’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$916K Sell
43,227
-250
-0.6% -$5.35K ﹤0.01% 1873
2026
Q1 		$951K Buy
43,477
+274
+0.6% +$6.1K ﹤0.01% 1692
2025
Q4 		$928K Hold
43,203
– – ﹤0.01% 1545
2025
Q3 		$506K Buy
+43,203
New +$430K ﹤0.01% 1782
2025
Q1 		– Sell
-12,085
Closed -$128K – 2358
2024
Q4 		$128K Sell
12,085
-12,149
-50% -$147K ﹤0.01% 2197
2024
Q3 		$354K Buy
+24,234
New +$344K ﹤0.01% 1934

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Corient Private Wealth's IMNM Position: Q2 2026 in Review

Corient Private Wealth reduced its Immunome (IMNM) stake by 0.58% in Q2 2026, selling an estimated $5.35K and leaving 43,227 shares worth $916K. The position accounts for ﹤0.01% of the portfolio, ranked #1873.

Corient Private Wealth first reported a position in IMNM in Q3 2024 and has held it in 6 quarters since. The position peaked at $951K in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Corient Private Wealth held 43,227 shares of Immunome worth $916K as of Q2 2026.
  • Corient Private Wealth sold 250 Immunome shares in Q2 2026, an estimated $5.35K.
  • Immunome made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1873 holding.
  • Corient Private Wealth first reported a position in Immunome in Q3 2024 and has held it in 6 quarters since.
  • Corient Private Wealth's Immunome position peaked at $951K in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.